SOT 2024 Newsletter

February 28, 2024

Please visit us at booth #1232 during ToxExpo. We have exciting information to share about new assays, test guidelines and more! In attendance will be: Amanda Ulrey (President), Kristie Sullivan (VP of Education and Outreach), Hans Raabe (COO), Holger Behrsing (Director of Respiratory Services), Vivek Patel and Allison Hilberer (Study Directors) and Brent Gilbert (Director of Business Development). (more…)

January 2024 Newsletter

January 26, 2024

Coming soon to IIVS: The Reactive Oxygen Species (ROS) Assay for photoreactivity, a cost effective, high throughput approach that can screen test compounds of interest without the immediate need for more comprehensive (and expensive) assays.      

October 2023 Newsletter

January 26, 2024

Recording of the two-part webinar series on in vitro phototoxicity, co-organized by IIVS and PETA Science Consortium International, now available online.          

August 2023 Newsletter

August 24, 2023

ToxTracker is a unique, stem-cell based assay which takes advantage of a Green Fluorescent Protein (GFP) reporter system to identify hazard and mode-of-action (MOA) of potentially genotoxic materials. On July 20th, IIVS was formally awarded ToxTracker Certification by Toxys, a Dutch Biotechnology company and the developers of the assay.

62nd Annual Meeting of the Society of Toxicology

March 14, 2023

IIVS is looking forward to exhibiting at the 62nd Annual Meeting of the Society of Toxicology! If attending, please visit us during ToxExpo at booth #834.        

March 2023 Newsletter

March 1, 2023

IIVS is pleased to share that the PMI In Vitro Alternatives Laboratory in Neuchâtel, Switzerland is now GIVIMP certified. Good In Vitro Method Practices (GIVIMP) is an OECD guidance document that provides a framework for quality standards specific to in vitro laboratory operations.

IIVS Leadership Newsletter

February 3, 2023

Please join me in congratulating Amanda Ulrey and Kristie Sullivan on their new roles as they work with Hans Rabe, Senior Vice President and Chief Operation Officer, and the rest of the IIVS team to further the IIVS mission of advancing the use and acceptance of non-animal approaches worldwide.

November 2022 Newsletter

November 10, 2022

IIVS is pleased to announce the appointment of Amanda Ulrey to our Board of Directors. As a 20-year veteran at IIVS, Mandy is currently Vice President of Business Operations and where she is primarily responsible for instituting quality management systems and regulatory compliance throughout the organization, as well as administering IIVS’ business-to-business certification in Good In Vitro Method Practices (GIVIMP).

What’s New at IIVS – Sept. 2022

September 14, 2022

Dr. Dan Bagley joins the IIVS Board of Directors; President of IIVS Recognized with Award by PCRM; Award for IIVS Training on Alternative Methods IIVS Toxicologist Dr. Argel Islas-Robles participated last week as speaker on the “In Vitro Science Webinars Series” focusing on the topic of non-Animal Methods for dermal and ocular testing on personal care and cosmetics (presentation in Spanish). This was first in a series of events designed to highlight New Approach Methodologies (NAMs) for human and environmental safety without the use of animal experimentation in Latin America.

May 2022 Newsletter

July 1, 2022

The ability to ascertain the maximum limit of a compound that can be applied to the skin without inducing skin sensitization is a critical safety criterion for virtually any risk assessment. Using regression models developed by Givaudan (Kempthal, Switzerland), IIVS is able to perform a computational approach to determine predicted EC3 values (Effective Concentration required to induce a 3-fold upregulation of lymph node cell proliferation) using a combination of OECD approved assays (KeratinoSens, hCLAT, and kDPRA). This value can be used to assess risk for compounds to be included in formulations.